HD-IMMUNE-GMBH
24.1.2024 04:41:35 CET | Business Wire | Press release
HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman. HDI has acquired the patents and assets of the Huntington’s disease program from AFFiRiS AG. HDI has also closed a pre-seed financing round with an Austrian Business Angel and awarded an Austria Wirtschafts Service (AWS) pre-seed Grant. Furthermore, HDI announces the successful application with the Austrian Centre of Industrial Biotechnology (acib) Comet24 program allowing for HDI to collaborate with the Institute of Molecular Biotechnology (BOKU, University of Natural Resources and Life Sciences, Vienna) for HDI’s research programs.
Dr. Stefan Bartl, CEO of HDI, comments: “With the acquirement of the Huntington’s disease program that I was developing previously at AFFiRiS AG, HD Immune starts in a position where we have very impressive pre-clinical data demonstrating the efficacy of treating transgenic model of Huntington’s Disease with our lead monoclonal antibody C6-17, which has been recently published. We are in the process of humanizing this antibody for the treatment of patients aiming to slow down the progression of the disease, thereby increasing the quality of life for the patient. Currently there are no therapies that can directly treat the mutant Huntingtin protein available for patients.”
HD Immune’s new pre-clinical publication can be found on the company webpage for downloading: www.hdimmune.com
HD Immune and Huntington’s Disease
Huntington’s disease (HD) is a fatal neurodegenerative disease with clinical symptoms becoming manifest typically in the fourth decade of life and progress to a severe neurological and psychiatric deterioration of the patient. HD is a rare monogenetic disorder, where the mutation leads to a structurally changed mutant Huntingtin protein (mtHTT) which forms aggregates in the brain.
HD Immune is developing an antibody to target the mutated protein and remove it from the body. HDI has a lead antibody mAB C6-17 which lowers mtHTT in the blood, organs and CNS and, further, improved motor performance in transgenic mice expressing human mutant protein. Based on these results, HD Immune intends to further advance the development of a human therapeutic antibody to reduce the symptoms of the disease in the patient.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122135838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
Andersen Global lancerer Andersen in Pakistan16.4.2026 22:57:00 CEST | Pressemeddelelse
Andersen Global fortsætter sin regionale vækst i Sydasien med tilføjelsen af Andersen in Pakistan som det seneste medlemsfirma, der slutter sig til den globale organisation. Efter overgangen til Andersen-brandet tilbyder virksomheden – tidligere kendt som Saafin Global Consulting – en bredt funderet praksis, der betjener kunder på tværs af brancher, herunder fremstillingsindustri, energi, finansielle tjenester, telekommunikation, sundhedsvæsen, fast ejendom og private equity. Med hovedkvarter i Islamabad leverer Andersen in Pakistan integreret support inden for skat, virksomhedsrådgivning og HR-tjenester til nationale og internationale organisationer. "Vores service er forankret i etik, styret af gennemsigtighed og bevist gennem et vedholdende engagement i præcision," udtalte Rashid Ibrahim, ledende partner hos Andersen in Pakistan. "At tage Andersen-brandet til os er en vigtig milepæl for vores firma. Det afspejler vores forpligtelse til at levere praktiske løsninger af høj kvalitet,
BTG Pactual Timberland Investment Group Completes First Close of US$ 370 Million to Newest Core Latin American Timberland Strategy16.4.2026 22:04:00 CEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, announced today that it has completed the first close of US$ 370 million in commitments to its newest core Latin America strategy. Targeting investment of US$ 1.5 billion over 5 years, the strategy focuses on large-scale, sustainably managed, core timberland assets across Chile, Uruguay and Brazil, and seeks diversification across geography, climatic zones, species, and end-markets. BTG Pactual TIG has operated in Latin America for over two decades, and has built and managed a series of scaled timberland platforms through this strategy, including the creation of three platform companies, Lumin, Vista Hermosa, and Plateau, forming part of the firm’s global US$ 7.5 billion portfolio. The formation of Plateau, announced in August 2025, marked the first acquisition under this new strategy. Created in partnership with Klabin S.A. (Klabin) and British Columbia Investment Mana
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom